UB Paderborn / Katalog / Suche / in CDI

1 – 6 von 6

Sortiert nach

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4357-4364

2009

Volltextzugriff (PDF)

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

Clinical cancer research, 2005-03, Vol.11 (5), p.1983-1989

2005

Volltextzugriff (PDF)

The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

Clinical cancer research, 2006-02, Vol.12 (3), p.924-932

2006

Volltextzugriff (PDF)

Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro

International immunopharmacology, 2004, Vol.4 (1), p.91-99

2004

Volltextzugriff (PDF)

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

British journal of haematology, 2007-11, Vol.139 (3), p.425-428

2007

Volltextzugriff (PDF)

Synthesis of the 7-Hydroxy Metabolites of Methotrexate and 10-Ethyl-10-Deazaaminopterin

Journal of pharmaceutical sciences, 1987-08, Vol.76 (8), p.635-638

1987

Volltextzugriff (PDF)

1 – 6 von 6

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6)
Mit Volltextzugriff
(6)

Publikationsform

Artikel
(6)

Sprache

Englisch
(6)
Japanisch
(3)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

Synthesis of the 7-Hydroxy Metabolites of Methotrexate and 10-Ethyl-10-Deazaaminopterin

Suchergebnisse filtern